ClinicalTrials.gg
CompletedNCT00002442Updated Jun 24, 2005

A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

A Phase 2 interventional study of Indinavir sulfate and Nelfinavir mesylate in HIV Infections, sponsored by Glaxo Wellcome. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Started
1999
with 8 others
Phase 2
24 of 132
none open now
Registered
1st of 132
by date
Lead sponsor
12 of 132
Glaxo Wellcome

Among the 132 studies testing lamivudine in HIV Infections, this one is one of 9 that started in 1999, is one of 24 in phase 2, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and effectiveness of 2 dosing schedules (once daily vs twice daily) of lamivudine (3TC) given with stavudine (d4T) and either indinavir (IDV) or nelfinavir (NFV) for 24 weeks.

Read the detailed description

Patients are randomized to 1 of 2 groups. Group 1 receives 3TC qd plus d4T plus either IDV or NFV. Group 2 receives 3TC bid plus d4T plus either IDV or NFV. Patients are evaluated for drug tolerance, medication adherence, and genotypic and phenotypic resistance.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Drug Therapy, Combination
  • Zidovudine
  • Drug Administration Schedule
  • Stavudine
  • HIV Protease Inhibitors
  • Lamivudine
  • Indinavir
  • Dosage Forms
  • Nelfinavir
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Are -positive.
  • Are at least 18 years old.
  • Have had an HIV level below 400 copies/ml for at least 3 months prior to study entry.
  • Have a of at least 50 cells/mm3.
  • Are currently taking an anti-HIV drug regimen that includes 3TC plus d4T plus either IDV or NFV for at least 6 months prior to study entry. (Note: This must be their first anti-HIV drug regimen.)
  • Agree to abstain from sex or use effective methods of during the study.

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have a history of an AIDS-defining illness or certain other medical conditions.
  • Are allergic to any of the study drugs.
  • Are unable to take medication by mouth for any reason.
  • Have received certain medications.
  • Will need to receive radiation therapy or chemotherapy (for any cancer other than Kaposi's sarcoma) during the study.
  • Are pregnant or breast-feeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
None (open label)
06

Study locations

12 sites
  • AIDS Healthcare Foundation
    Los Angeles, California 90027, United States
  • Palo Alto Veterans Affairs Health Care System
    Palo Alto, California 94304, United States
  • Dupont Circle Physicians Group
    Washington, District of Columbia 200091104, United States
  • IDC Research Initiative
    Altamonte Springs, Florida 32701, United States
  • North Broward Hosp District
    Fort Lauderdale, Florida 33316, United States
  • Steinhart Medical Associates
    Miami, Florida 33133, United States
  • Northwestern Univ Med School
    Chicago, Illinois 60611, United States
  • Saint Vincents Hosp
    New York, New York 10011, United States
  • St Lukes - Roosevelt Hosp Ctr
    New York, New York 10019, United States
  • MCP Hahnemann Univ Hosp
    Philadelphia, Pennsylvania 19102, United States
  • Southwest Infectious Disease Association / PA
    Dallas, Texas 75225, United States
  • Univ TX Galveston Med Branch
    Galveston, Texas 77550, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002442
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Start date
Jun 1999
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2000. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamivudine

Start the discussion